Stockscreener 앱 받기
353.68
0.67%
-2.40
시간 외 거래:
353.68
전일 마감가:
$356.08
열려 있는:
$351.9
하루 거래량:
917.80K
Relative Volume:
1.09
시가총액:
$24.99B
수익:
$3.22B
순이익/손실:
$542.70M
주가수익비율:
47.28
EPS:
7.4805
순현금흐름:
$458.00M
1주 성능:
-3.10%
1개월 성능:
+10.61%
6개월 성능:
+28.50%
1년 성능:
+60.41%
1일 변동 폭
$349.41
$355.51
1주일 범위
$349.41
$367.66
52주 변동 폭
$206.80
$367.66
West Pharmaceutical Services Inc Stock (WST) Company Profile
명칭
West Pharmaceutical Services Inc
전화
(610) 594-2900
주소
530 HERMAN O. WEST DRIVE, EXTON, PA
Compare WST vs ISRG, BDX, MDLN, ALC, RMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
WST
West Pharmaceutical Services Inc
|
353.68 | 25.16B | 3.22B | 542.70M | 458.00M | 7.4805 |
ISRG
Intuitive Surgical Inc
|
415.10 | 151.33B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
150.56 | 43.07B | 21.37B | 1.41B | 3.07B | 3.9437 |
MDLN
Medline Inc
|
40.30 | 36.37B | 29.14B | 1.07B | 1.05B | 1.1956 |
ALC
Alcon Inc
|
66.56 | 32.61B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
205.84 | 31.88B | 5.54B | 1.52B | 1.74B | 10.37 |
West Pharmaceutical Services Inc Stock (WST) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-02 | 개시 | Morgan Stanley | Equal-Weight |
| 2025-09-15 | 개시 | Rothschild & Co Redburn | Buy |
| 2025-06-24 | 개시 | Barclays | Equal Weight |
| 2025-03-18 | 개시 | Evercore ISI | Outperform |
| 2025-02-14 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-01-08 | 개시 | Citigroup | Buy |
| 2024-12-13 | 개시 | Wolfe Research | Peer Perform |
| 2024-12-12 | 업그레이드 | UBS | Neutral → Buy |
| 2024-02-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-06-16 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-04-11 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2022-12-14 | 개시 | Deutsche Bank | Hold |
| 2022-11-30 | 개시 | UBS | Neutral |
| 2022-10-28 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2020-10-14 | 개시 | Stephens | Equal-Weight |
| 2020-07-21 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-04-24 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2019-12-12 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2019-07-26 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2019-05-01 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-04-23 | 개시 | William Blair | Outperform |
| 2018-04-25 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2017-10-17 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2017-10-03 | 개시 | Stephens | Equal-Weight |
| 2017-09-15 | 업그레이드 | Jefferies | Hold → Buy |
| 2016-10-28 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2016-09-21 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2016-03-22 | 개시 | Wells Fargo | Outperform |
| 2010-05-14 | 재확인 | UBS | Neutral |
| 2010-02-23 | 개시 | Jefferies & Co | Buy |
| 2008-12-19 | 개시 | UBS | Neutral |
모두보기
West Pharmaceutical Services Inc 주식(WST)의 최신 뉴스
The Daikyo D2F Series PlungerWest Pharmaceutical focuses on high-barrier safety for prefilled syr - AD HOC NEWS
WST stock up nearly 33% YTD: Will the uptrend continue in the rest of 2026? - MSN
West Pharmaceutical Services (WST) Is Up 4.24% in One Week: What You Should Know - Yahoo Finance
Here's Why You Should Retain AMN Stock in Your Portfolio for Now - TradingView
West to Host Second-Quarter 2026 Conference Call - TradingView
WST Maintains Rating by Evercore ISI Group -- Price Target Raises to $410 - GuruFocus
West Pharmaceutical Services Inc. stock underperforms Monday when compared to competitors - MarketWatch
West Pharmaceutical updates strategy as global demand for drug delivery grows - AD HOC NEWS
West Pharmaceutical Services (WST) Stock Looks Overvalued Despite Upcoming Q2 Earnings - Yahoo Finance
WST Stock Up Nearly 33% YTD: Will the Uptrend Continue in the Rest of 2026? - TradingView
Did You Lose Money on West Pharmaceutical Services, Inc. (WST)? L - The National Law Review
West Pharmaceutical Services Stock 10-Day Winning Spree: Stock Climbs 13% - Trefis
West Pharmaceutical rises on upbeat results, guidance raise - MSN
Here's Why You Should Retain McKesson Stock in Your Portfolio for Now - TradingView
West completes sale of on-body drug delivery device to AbbVie - Drug Delivery Business
West Pharmaceutical Services Stock Rockets 13% With 9-Day Winning Streak - Trefis
What to Expect From West Pharmaceutical Services' Q2 2026 Earnings Report - Yahoo Finance
KeyBanc Maintains West Pharmaceutical Services(WST.US) With Buy Rating, Raises Target Price to $390 - Moomoo
West Pharmaceutical Services (WST) Is Up 6.7% After 21% Revenue Growth on Drug Delivery Demand - Sahm
West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System - Sahm
KeyBanc Adjusts PT on West Pharmaceutical Services to $390 From $350, Maintains Overweight Rating - marketscreener.com
West Pharmaceutical completes sale of SmartDose 3.5mL system By Investing.com - Investing.com Australia
Form 4 West Pharmaceutical Services Inc For: 1 July By Investing.com - Investing.com Canada
West Pharmaceutical (WST) director awarded new phantom stock units and RSUs - Stock Titan
West Pharmaceutical completes sale of SmartDose 3.5mL system - Investing.com
West Pharmaceutical Services Inc. stock outperforms competitors on strong trading day - MarketWatch
West Pharmaceutical Services stock hits 52-week high at 363.38 USD - Investing.com
Westar™ RS LyoVials from West Pharmaceuticalmodular containment for complex injectables - AD HOC NEWS
West Pharmaceutical Services (WST) Is Up 6.7% After 21% Revenue Jump On Injectable DemandHas The Bull Case Changed? - Yahoo Finance
West Pharmaceutical Services, Inc.'s stock price skyrockets to $359.00, boasting a promising 1.22% increase - Smartkarma
Here's Why You Should Add BrightSpring Stock to Your Portfolio Now - TradingView
WST Technical Analysis & Stock Price Forecast - Intellectia AI
The SmartDose Gen. II injector from West Pharmaceutical Services Inc.wearable biologics delivery - AD HOC NEWS
West Pharmaceutical Services Inc. stock rises Monday, still underperforms market - MarketWatch
West Pharmaceutical focuses on long term growth, shares steady in S&P 500 healthcare segment - AD HOC NEWS
West Pharmaceutical Services (WST) Stock Analysis: Strong Revenue Growth and Bullish Analyst Ratings Offer Promising Prospects - DirectorsTalk Interviews
West Pharmaceutical Services Inc. (WST) Edges Higher as It Holds Above Key SupportBear Pennant - dars.gov.et
West Pharmaceutical Services earnings date approaches, shares backed by analyst interest - AD HOC NEWS
WST DEADLINE: ROSEN, A LEADING AND RANKED FIRM, Encourages West Pharmaceutical Services, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important July 7 Deadline in Securities Class ActionWST - TMX Newsfile
Class Action Alert: Levi & Korsinsky Reminds West Pharmaceutical - The National Law Review
WST LAWSUIT ALERT: Levi & Korsinsky Notifies West Pharmaceutical - The National Law Review
West Pharmaceutical Services names Michel Lagarde as next CEO, effective Aug. 31 - MSN
Lost Money on West Pharmaceutical Services, Inc. (WST)? Urged to - The National Law Review
Class Action Lawsuit Filed: West Pharmaceutical Services, Inc. (WST) – Join by July 7, 2025Contact Levi & Korsinsky - The National Law Review
West Pharmaceutical steady on Friday, S&P 500 peer group shows mixed moves - AD HOC NEWS
Price to earnings forward of West Pharmaceutical Services, Inc. – NYSE:WST - TradingView
Is West Pharmaceutical stock outperforming the S&P 500? - MSN
Vest S&P 500 Dividend Aristocrats Target Income Fund's West Pharmaceutical Services Inc(WST) Holding History - GuruFocus
West Pharmaceutical adjusts guidance on GLP-1 demand, shares extend 30-day gain - AD HOC NEWS
Westar RS Lined Seal from West Pharmaceutical Services Inc.ready-for-use vial closure targets con - Ad-hoc-news.de
West Pharmaceutical Services, Inc. Actuals & Estimates (NYSE:WST) - TradingView
West Pharmaceutical Services Inc (WST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
6.33%
자본화:
|
볼륨(24시간):